A298380 Stock Overview
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ABL Bio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩25,250.00 |
| 52 Week High | ₩30,500.00 |
| 52 Week Low | ₩15,370.00 |
| Beta | 1.08 |
| 1 Month Change | -5.25% |
| 3 Month Change | 19.39% |
| 1 Year Change | 15.83% |
| 3 Year Change | 11.73% |
| 5 Year Change | -25.30% |
| Change since IPO | 84.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| A298380 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 17.4% | 5.4% | 3.4% |
| 1Y | 15.8% | 6.7% | 7.1% |
Return vs Industry: A298380 exceeded the KR Biotechs industry which returned 6.6% over the past year.
Return vs Market: A298380 exceeded the KR Market which returned 4.7% over the past year.
Price Volatility
| A298380 volatility | |
|---|---|
| A298380 Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A298380 has not had significant price volatility in the past 3 months.
Volatility Over Time: A298380's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Sang Hoon Lee | www.ablbio.com |
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam-si, South Korea.
ABL Bio Inc. Fundamentals Summary
| A298380 fundamental statistics | |
|---|---|
| Market cap | ₩1.21t |
| Earnings (TTM) | -₩2.65b |
| Revenue (TTM) | ₩65.55b |
18.4x
P/S Ratio-456.9x
P/E RatioIs A298380 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A298380 income statement (TTM) | |
|---|---|
| Revenue | ₩65.55b |
| Cost of Revenue | ₩46.25m |
| Gross Profit | ₩65.50b |
| Other Expenses | ₩68.15b |
| Earnings | -₩2.65b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -55.26 |
| Gross Margin | 99.93% |
| Net Profit Margin | -4.04% |
| Debt/Equity Ratio | 58.0% |
How did A298380 perform over the long term?
See historical performance and comparison